IP Library › Granted Patent US 11,358,997
Granted Patent B2
US 11,358,997 · App. 16/103,302 · Granted Jun 14, 2022

Fusokines involving cytokines with strongly reduced receptor binding affinities

Inventors: Jan Tavernier (Balegem, BE); Jennyfer Bultinck (Ledeberg, BE); Sarah Gerlo (Ghent, BE); Gilles Uze (Montpellier, FR); Franciane Paul (Montpellier, FR); Yann Bordat (Montpellier, FR)
Assignees: VIB VZW; Universiteit Gent; Centre National De La Recherche Scientifique; Université De Montpellier; Centre Hospitalier Regional Universitaire de Montpellier
C07K14/521A61K38/195A61K38/2006A61P37/04C07K14/52C07K14/523C07K14/525C07K14/545C07K14/56C07K14/5759C07K2319/00C07K2319/33C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,358,997
App. No.
16/103,302
Granted
Jun 14, 2022
Kind
B2
Abstract

The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.

Claims (9)

1. A composition comprising a protein consisting of two cytokines and a linker,

wherein the cytokines are human chemokine (C motif) ligand (XCL1) and human interferon alpha 2 (IFNα2), and

the IFNα2 comprises a mutation that reduces binding activity to its receptor as compared to wild-type IFNα2,

and XCL1 is wild-type and provides cell-specific targeting that restores activity of the mutant IFNα2 on the targeted cells.

2. The composition of claim 1 , wherein the linker is one or more GSS repeats.

3. A method of stimulating an immune response in a cell, comprising contacting the cell with a composition comprising a protein consisting of a two cytokines and a linker,

wherein the cytokines are human XCL1 and human IFNα2, and

the IFNα2 has a mutation which provides reduced affinity for its receptor as compared to wild-type IFNα2 and XCL1 is wild-type and provides cell-specific targeting that restores activity of the mutant IFNα2 on the targeted cells.

4. The method of claim 3 , wherein the linker is one or more GSS repeats.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2022
From: TAVERNIER, JAN; BULTINCK, JENNYFER; GERLO, SARAH; UZÈ, GILLES; PAUL, FRANCIANE; BORDAT, YANN
To: VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2; CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
Reel/Frame 061903/0575 →
MERGER AND CHANGE OF NAME Recorded Nov 29, 2022
From: UNIVERSITE MONTPELLIER 2; UNIVERSITÉ DE MONTPELLIER
To: UNIVERSITÉ DE MONTPELLIER
Reel/Frame 062257/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2019
From: TAVERNIER, JAN; BULTINCK, JENNYFER; GERLO, SARAH; UZE, GILLES; PAUL, FRANCIANE; BORDAT, YANN
To: VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITÉ MONTPELLIER 2; CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
Reel/Frame 048804/0083 →
MERGER AND CHANGE OF NAME Recorded Apr 5, 2019
From: UNIVERSITÉ MONTPELLIER 2; UNIVERSITÉ DE MONTPELLIER
To: UNIVERSITÉ DE MONTPELLIER
Reel/Frame 048813/0949 →
Priority Claims (1)
EP 13306034 · Jul 18, 2013 · regional
Continuity (2)
Division 14905343
Related Publication 20190010199A1 · Jan 10, 2019
Cited By (2)
US 12,576,127 US 12,583,941